NovaBay Pharmaceuticals, Inc. announced that Mark M. Sieczkarek's positions as the President and Chief Executive Officer of company terminated upon the appointment of the Interim President and Chief Executive Officer by the Company's Board of Directors effective September 28, 2018. Mr. Sieczkarek will remain as the Chairman of the Board. Effective September 28, 2018, the Board appointed John J. McGovern, the Company's current Chief Financial Officer and Treasurer, as the Interim President and Chief Executive Officer of the Company, replacing Mr. Sieczkarek from these positions.

Mr. McGovern is expected to serve as the Interim President and Chief Executive Officer until the Company completes its search process for a successor President and Chief Executive Officer. Mr. McGovern will continue to serve as the Chief Financial Officer and Treasurer of the Company during the interim period. Mr. McGovern has served as the Company's Chief Financial Officer and Treasurer since July 2017.